Hair Loss Treatment Market Comprehensive Analysis, Share, Growth Forecast from 2020 to 2026

Hair loss is a common condition and it can be caused by numerous disorders. Hair loss or alopecia begins after the onset of puberty. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens that affects around 50% of males and females globally, according to the National Center for Biotechnology Information (NCBI). It is characterized by progressive loss of terminal hair of the scalp, in a characteristic distribution in both males and females. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women the frontal hairline is typically spared with diffuse apical hair loss noted as a wider anterior part of the hair.

Major players operating in the global hair loss treatment market include Viviscal, Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, Ranbaxy Laboratories Ltd, HCell Inc., Follica, Inc., Aurobindo Pharma, and Zydus Pharmaceuticals, Inc. (Zydus Cadila), among others.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/4374

Market Dynamics

Rising incidence of androgenetic alopecia is expected to drive the global hair loss treatment market growth. For instance, according to the National Library of Medicine (NLM), a medical library, which is part of the National Institutes of Health (NIH), androgenetic alopecia affects around 50 million men and 30 million women in the U.S.

However, availability of alternative treatments is expected to hinder the market growth. For instance, hair restoration surgery such as scalp reduction surgeries, which is not used frequently but efficacy of hair transplantation is based on the principle of donor dominance.

Hair loss is caused due to systemic androgen and genetic factors. It may occur in both genders. The increasing incidence of alopecia or hair loss is expected to boost the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), in August 2015, global prevalence of severe androgenetic alopecia (AGA) was 15.33% and varied significantly by geographical regions. The same source states that risk of having severe androgenetic alopecia (AGA) increases by 1.092 for per year in the age group of 30 and 40.

The global hair loss treatment market is estimated to be valued at US$ 3,592.3 million in 2020 and is expected to exhibit a CAGR of 6.2% during the forecast period (2020-2027).

Product development and ongoing clinical trials are expected to propel growth of the global hair loss treatment market.

Development of drugs for hair loss treatment is expected to boost the market growth over the forecast period. For instance, Cairo University has initiated clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females. The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021.

However, side effects of hair loss treatment is expected to hinder the market growth. For instance, according to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018, stated that medication used for the treatment of androgenetic alopecia exhibit several side effects. For instance, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension, and others.

Research and development for the treatment of androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global hair loss treatment market, owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development in 2020, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

You can Buy This Report from Here @ https://www.coherentmarketinsights.com/insight/buy-now/4374

Global Hair Loss Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global hair loss treatment market during the forecast period.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.